Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
Фаза 3
Прекращено
NCT04251533
| Заболевание | Triple Negative Breast Neoplasms |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | Novartis Pharmaceuticals |
|---|
| Статус | Прекращено |
|---|
| Участники | 137 участн. |
|---|
| Вмешательство | alpelisib, nab-paclitaxel |
|---|
| Дата начала | 8.06.2020 |
|---|
| Дата завершения | 31.05.2023 |
|---|
| Публикация результатов | 31.07.2024 |
|---|
Кратко
The purpose of this study was to determine whether treatment with alpelisib in combination with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who carry either a PIK3CA mutation (Study Part A) or have PTEN loss (Study Part B1) or PTEN loss without PIK3CA mutation (Study Part B2)
Progression-free Survival (PFS) Per Investigator Assessment in Study Part A
Once all participants have completed at least 6 months of study treatment or have discontinued from study treatment, up to 35 months · months
| Part A: Alpelisib + Nab-paclitaxel | 7.2 months |
|---|
| Part A: Placebo + Nab-paclitaxel | 5.6 months |
|---|
| Hazard Ratio (HR) | 1.49 (95% CI 0.92–2.41) |
|---|
Overall Response Rate (ORR) Based on Local Radiology Assessments in Participants With Measurable Disease at Baseline in Study Part B1
Up to 6 months · percentage of participants
| Part B1: Alpelisib + Nab-paclitaxel | 14.3 percentage of participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.